251 related articles for article (PubMed ID: 2458320)
1. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci.
Bessen D; Fischetti VA
Infect Immun; 1988 Oct; 56(10):2666-72. PubMed ID: 2458320
[TBL] [Abstract][Full Text] [Related]
2. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.
Bessen D; Fischetti VA
J Immunol; 1990 Aug; 145(4):1251-6. PubMed ID: 1696296
[TBL] [Abstract][Full Text] [Related]
3. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
Bronze MS; Courtney HS; Dale JB
J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
[TBL] [Abstract][Full Text] [Related]
4. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
Olive C; Clair T; Yarwood P; Good MF
Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
[TBL] [Abstract][Full Text] [Related]
5. Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant.
Fischetti VA; Hodges WM; Hruby DE
Science; 1989 Jun; 244(4911):1487-90. PubMed ID: 2660266
[TBL] [Abstract][Full Text] [Related]
6. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
[TBL] [Abstract][Full Text] [Related]
7. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
8. Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections.
Dale JB; Chiang EC
J Infect Dis; 1995 Apr; 171(4):1038-41. PubMed ID: 7706785
[TBL] [Abstract][Full Text] [Related]
9. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
[TBL] [Abstract][Full Text] [Related]
10. Intranasal immunisation of mice with a streptococcal peptide-based vaccine.
Relf W; Hayman W; Russell-Jones G; Good M
Adv Exp Med Biol; 1997; 418():859-61. PubMed ID: 9331788
[No Abstract] [Full Text] [Related]
11. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
[TBL] [Abstract][Full Text] [Related]
12. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.
Wu HY; Russell MW
Infect Immun; 1993 Jan; 61(1):314-22. PubMed ID: 8418053
[TBL] [Abstract][Full Text] [Related]
13. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
[TBL] [Abstract][Full Text] [Related]
14. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.
Dale JB
Vaccine; 1999 Jan; 17(2):193-200. PubMed ID: 9987154
[TBL] [Abstract][Full Text] [Related]
15. Role of M protein in pharyngeal colonization by group A streptococci in rats.
Hollingshead SK; Simecka JW; Michalek SM
Infect Immun; 1993 Jun; 61(6):2277-83. PubMed ID: 8500869
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
Bronze MS; McKinsey DS; Beachey EH; Dale JB
Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
[No Abstract] [Full Text] [Related]
17. Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci.
Pruksakorn S; Currie B; Brandt E; Martin D; Galbraith A; Phornphutkul C; Hunsakunachai S; Manmontri A; Good MF
Lancet; 1994 Sep; 344(8923):639-42. PubMed ID: 7520963
[TBL] [Abstract][Full Text] [Related]
18. In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci.
Nordström T; Malcolm J; Magor G; Good MF; Batzloff MR
Clin Vaccine Immunol; 2012 Dec; 19(12):1984-7. PubMed ID: 23081813
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB
Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757
[TBL] [Abstract][Full Text] [Related]
20. Mapping T-cell epitopes in group A streptococcal type 5 M protein.
Robinson JH; Atherton MC; Goodacre JA; Pinkney M; Weightman H; Kehoe MA
Infect Immun; 1991 Dec; 59(12):4324-31. PubMed ID: 1718873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
